Medpace Holdings, Inc. to Report Second Quarter 2024 Financial Results on July 22, 2024
Medpace Holdings, Inc. to Report Second Quarter 2024 Financial Results on July 22, 2024
CINCINNATI--(BUSINESS WIRE)--Jun. 26, 2024-- Medpace Holdings, Inc. (Nasdaq: MEDP) ("Medpace") today announced that it will report its second quarter 2024 financial results after the market close on Monday, July 22, 2024. The Company will host a conference call the following morning, Tuesday, July 23, 2024, at 9:00 a.m. ET to discuss these results.
美迪康（medpace）控股有限公司（Nasdaq：MEDP）宣佈將於2024年7月22日（週一）收盤後發佈2024年第二季度財務業績，並於2024年7月23日（週二）上午9:00（美國東部時間）召開電話會議，討論這些結果。
To participate in the conference call, interested parties must register in advance by clicking on this link. While it is not required, it is recommended you join 10 minutes prior to the event start. Upon registration, all telephone participants will receive a confirmation email detailing how to join the conference call, including the dial-in number along with a unique PIN that can be used to access the call.
如需參加電話會議，有興趣的各方必須提前註冊，單擊鏈接即可。雖然這不是必需的，但建議您提前10分鐘加入該活動。註冊後，所有電話參與者都將收到一封確認電子郵件，詳細介紹如何參加電話會議，包括撥入號碼以及可用於訪問電話會議的唯一PIN碼。此鏈接要通過網絡廣播訪問電話會議，請訪問medpace的“投資者”部分的網站investor.medpace.com。電話會議回放將在會議結束約一小時後在同一網站上提供。
To access the conference call via webcast, visit the "Investors" section of Medpace's website at investor.medpace.com. The webcast replay of the call will be available at the same site approximately one hour after the end of the call.
要在電話會議開始前通過“投資者”部分的medpace網站獲得補充幻燈片演示文稿。investor.medpace.com電話會議的網絡廣播回放將在會議結束約一小時後在同一網站上提供。
A supplemental slide presentation will also be available at the "Investors" section of Medpace's website prior to the start of the call.
美迪康是一家全球範圍內提供一流科研及研發服務的醫療組織（CRO），其業務範圍覆蓋生物技術、製藥和醫療設備等行業，致力於通過高科技及嚴謹的運營方式，在所有主要領域，包括腫瘤學、心臟病學、代謝病學、內分泌學、中樞神經系統和抗病毒及抗感染等領域整合監管和治療專業知識，以加速全球安全有效的醫學治療方案開發。總部位於俄亥俄州辛辛那提市，截至2024年3月31日，美迪康在42個國家擁有約5,800名員工。
About Medpace
關於Medpace
Medpace is a scientifically-driven, global, full-service clinical contract research organization (CRO) providing Phase I-IV clinical development services to the biotechnology, pharmaceutical and medical device industries. Medpace's mission is to accelerate the global development of safe and effective medical therapeutics through its high-science and disciplined operating approach that leverages regulatory and therapeutic expertise across all major areas including oncology, cardiology, metabolic disease, endocrinology, central nervous system and anti-viral and anti-infective. Headquartered in Cincinnati, Ohio, Medpace employs approximately 5,800 people across 42 countries as of March 31, 2024.
Medpace是一家以科學爲驅動，全球範圍內提供I-IV臨床開發服務的全方位臨床合同研究組織（CRO），爲生物技術、製藥和醫療器械行業提供服務。Medpace的使命是通過高科技和嚴謹的運營方法加快全球安全有效醫療療法的開發，利用所有主要領域的監管和治療專業知識，包括腫瘤、心臟病學、代謝疾病、內分泌學、中樞神經系統和抗病毒和抗感染。總部位於俄亥俄州辛辛那提市，截至2024年3月31日，Medpace在42個國家擁有約5800名員工。
View source version on businesswire.com: https://www.businesswire.com/news/home/20240626082979/en/
在businesswire.com上查看原始版本businesswire.com: https://www.businesswire.com/news/home/20240626082979/en/
Investor Contact:
Lauren Morris
513.579.9911 x11994
l.morris@medpace.com
投資者聯繫：
Lauren Morris
513.579.9911 x11994
l.morris@medpace.com
Media Contact:
Julie Hopkins
513.579.9911 x12627
j.hopkins@medpace.com
媒體聯繫人：
Julie Hopkins
513.579.9911 x12627
j.hopkins@medpace.com
Source: Medpace Holdings, Inc.
資訊來源：美迪康控股有限公司。
譯文內容由第三人軟體翻譯。